Thomas Evans

Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma.

Mark R. Middleton, Neil Steven, Thomas Evans et al. · Journal of Clinical Oncology · 2016 · 44 citations

Medicine, Oncology, Pharmacology +17

Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study

Theresa Medina, Jason Chesney, Harriet M. Kluger et al. · Journal of Clinical Oncology · 2025 · 32 citations

Life Sciences, Immunology, Oncology +17

HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors

Mary E. Molloy, Wade H. Aaron, Manasi Barath et al. · Molecular Cancer Therapeutics · 2024 · 29 citations · Full text

Life Sciences, Immunology, Oncology +17

Final results from cohort 1 of a phase II study of volociximab, an anti-α5β1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC)

Thomas Evans, Rajesh Ramanathan, Salim Yazji et al. · Journal of Clinical Oncology · 2007 · 25 citations

Medicine, Oncology, Pharmacology +17

Preclinical and Nonclinical Characterization of HPN217: A Tri-Specific T Cell Activating Construct (TriTAC) Targeting B Cell Maturation Antigen (BCMA) for the Treatment of Multiple Myeloma

Che‐Leung Law, Wade H. Aaron, Rick Austin et al. · Blood · 2018 · 19 citations

Life Sciences, Immunology, Oncology +14